Medical network - on March 30, in the backdrop of the health control fee, with the depth of industry policy adjustment, the pharmaceutical industry listed companies results manifest the characteristics of differentiation. Some listed companies affected by the dividend policy, industry warmed to achieve results, and some of the listed companies is affected by the policy change performance. 

 

As of March 28, according to the "industry classification, a-share listed companies A total of 164 medical biological earnings forecast, 79 listed companies released A complete transcript. In the listed company earnings forecast, 129 listed companies performance is expected to grow. In published reports of listed companies, 19 performance of listed companies fell. 

 

▍ wide reputation far growth in the first place 

 

"2016 is much starker choices-and graver consequences-in the start of the implementation of pharmaceutical research and development, production, circulation, pay intensive areas such as reform policies, the pharmaceutical industry is under profound changes, and affected by the macroeconomic situation, the pharmaceutical industry growth is slowing as a whole." People f medicine released in late March 28, 2016 annual report said. 

 

People f medicine, said the company achieve the business income is 12.33 billion yuan last year, up 22.65% from 2015. Realize net profit attributable to shareholders of listed companies of 832.4034 million yuan, up 27.31% from 2015. 

 

Besides people f medicine, released the 2016 annual report of listed companies, and 59 listed company performance. Ten of the listed company implement multiple growth, wide reputation far net profit growth of the first in the industry. 

 

According to wide reputation far released 2016 annual report, company operating income of 936.9932 million yuan, up 118.7% from a year earlier, the net profit of 122.8101 million yuan, up 5948.84% from a year earlier. Wide reputation far, the company "high-quality goods of traditional Chinese medicine (TCM) + + Chinese medicine health wine" three big business sector development to get strong support, hospitals, OTC, rapid growth of business, such as terminal channel, plus further optimization of product structure, the sales rate, effectively reduce the company operating income, net profit attributable to the parent company shareholders to increase rapidly. 

 

Broad economic pharmaceutical last year net profit attributable to shareholders of listed companies of 140 million yuan, up 577.96%; Anti-lu medicine to achieve net profit attributable to shareholders of listed companies of 29.102 million yuan, up 268.51% from 2015. Garden biological implementation belongs to public shareholders net income of 43.772 million yuan, up 262.52%; New and into a net profit of 1.2 billion yuan last year, up 199.11% from a year earlier. In addition, Tibetan medicine, essence pharmaceutical performance of listed companies increase by more than 100%. 

 

It is understood that widely dhi pharmaceutical, new, and become as the leading product price rising company performance. 

 

▍ 19 declining performance of listed companies 

 

Wide reputation far compared such as the performance of listed companies, some listed companies are feeling the development of the industry of "cold". 

 

Wisdom fly biological achieve revenue of about 446 million yuan last year, fell 37.43% year on year; Net profit attributable to shareholders of listed companies of 32.52 million yuan, down 83.53% year-on-year. Wisdom flying creatures, during the reporting period, the company industry great changes have taken place in the factors such as policy, market. Countries revised the regulations on the administration of the circulation of vaccines and vaccination, larger changes to existing vaccines standards and policies, the vaccine procurement, distribution phase adopted a new service mode, to the manufacturer's distribution ability, service ability and level put forward higher requirements; At the same time, because the public opinion of "hesitation" vaccine inoculation units during a certain period of the distribution of vaccine can be collected, used, brought vaccine enterprise sales channels, has increased the risk of returns. 

 

In addition, biological performance, according to letters released Watson promulgated by the state council of the revised regulations on the administration of the circulation of vaccines and vaccination, the vaccine circulation enterprise all cannot be engaged in vaccine wholesale business, the company vaccine agent revenue reduction, the company operating income in 2015 to reduce 511.8425 million yuan, the damping is 41.25%. 

 

WoHua medicine released 2016 annual report showed that last year, the company business revenue of 562.8456 million yuan, a 20.03% increase from the same period in 2015, a 48.8094 million - yuan net profit attributable to shareholders of listed companies, 31.61% lower than in 2015. For the cause of the performance change, WoHua medicine, said during the reporting period to deal with the fierce market competition, the company increased investment in the marketing, reduce the net profit. 

 

Xiangxue pharmacy 2016 results letters released by the company last year operating income of 1.916 billion yuan, up 30.84%; A 73.683 million - yuan net profit attributable to shareholders of listed companies, fell 58.44%. Xiangxue pharmacy, said during the reporting period, the company's overall operating performance of the reasons for the decline is mainly affected by medical insurance fee, medicine circulation field change, a new round of drug bidding procurement, reduce the effects of factors such as medicine of public hospital, and market competition, especially the OTC channels increasingly intensified competition, has certain influence on 2016 performance. 

 

Double into drug release performance in 2016 letters, according to the company business revenue of about 150 million yuan last year, estimates, fell 36.46% year on year; Operating profit loss about 377 million yuan. Net profit attributable to shareholders of listed companies loss of 376 million yuan. Double into pharmaceutical industry are introduced, the cause of the company 2016 annual performance loss include: during the reporting period, some varieties for the bidding policy changes led to the decrease of the price has certain and slowing sales; Company's internationalization strategy implementation greatly increased r&d investment; Taking a stake in the company of hangzhou, the biological technology co., LTD., the decline of the business performance, provision for impairment loss of long-term equity investment as stipulated in the accounting standards for 277.569 million yuan.